How Does the Experimental ‘Vaccine’ for Celiac Disease Work?
Page 1 of 1
How Does the Experimental ‘Vaccine’ for Celiac Disease Work?
An experimental "vaccine" for celiac disease is set to be tested in a new clinical trial to see if the treatment can protect patients with the condition from the effects of eating gluten — or, in other words, allow those patients to eat gluten safely. The treatment, called Nexvax2 and made by the biotech company ImmusanT Inc., is a type of immunotherapy that aims to "reprogram" the immune system to be tolerant of gluten, the researchers said.
Celiac disease is a condition in which people's immune systems react abnormally to gluten — a protein found in wheat, rye and barley — and this reaction damages the lining of the small intestine. The condition affects about 1 out of every 100 people in the United States. Currently, the only way to manage celiac disease is for patients to avoid foods containing gluten for the rest of their lives. But even with the rise in popularity of gluten-free foods, such diets can still be difficult to follow, and patients may be inadvertently exposed to the protein. "Even the most diligent patients can suffer the adverse effects of accidental exposure," study researcher Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, said in an Oct. 30 statement.
Nexvax2 works in a way that's similar to allergy shots. The treatment — which consists of twice-weekly injections administered over a 16-week period — is made up of molecules called peptides, which elicit an immune response in patients with celiac disease. In theory, exposure to the peptides over time could help reprogram immune cells called T cells to become tolerant of gluten and no longer trigger an immune response to the substance, according to ImmusanT. This could allow patients with celiac disease to eat a diet that includes gluten.
The vaccine is intended for patients with celiac disease who carry an immune system gene called HLA-DQ2.5 that is found in about 90 percent of individuals with the condition, the company said.
In an earlier trial of Nexvax2 in a small group of people, researchers showed that the vaccine was safe and well-tolerated among patients with celiac disease. The new study, which will include around 150 patients, aims to further test the safety, as well as the effectiveness of the treatment.
"This [new] trial is important in establishing clinical proof of concept for a treatment that would provide benefit beyond that of the gluten-free diet," Tye-Din said. (Proof of concept means that the trial would show that the treatment works as intended.)
The company is currently recruiting patients in Australia, New Zealand and the United States to participate in the trial, according to ClinicalTrials.gov.
livescience.com/64050-experimental-gluten-vaccine-nexgen2.html
Celiac disease is a condition in which people's immune systems react abnormally to gluten — a protein found in wheat, rye and barley — and this reaction damages the lining of the small intestine. The condition affects about 1 out of every 100 people in the United States. Currently, the only way to manage celiac disease is for patients to avoid foods containing gluten for the rest of their lives. But even with the rise in popularity of gluten-free foods, such diets can still be difficult to follow, and patients may be inadvertently exposed to the protein. "Even the most diligent patients can suffer the adverse effects of accidental exposure," study researcher Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, said in an Oct. 30 statement.
Nexvax2 works in a way that's similar to allergy shots. The treatment — which consists of twice-weekly injections administered over a 16-week period — is made up of molecules called peptides, which elicit an immune response in patients with celiac disease. In theory, exposure to the peptides over time could help reprogram immune cells called T cells to become tolerant of gluten and no longer trigger an immune response to the substance, according to ImmusanT. This could allow patients with celiac disease to eat a diet that includes gluten.
The vaccine is intended for patients with celiac disease who carry an immune system gene called HLA-DQ2.5 that is found in about 90 percent of individuals with the condition, the company said.
In an earlier trial of Nexvax2 in a small group of people, researchers showed that the vaccine was safe and well-tolerated among patients with celiac disease. The new study, which will include around 150 patients, aims to further test the safety, as well as the effectiveness of the treatment.
"This [new] trial is important in establishing clinical proof of concept for a treatment that would provide benefit beyond that of the gluten-free diet," Tye-Din said. (Proof of concept means that the trial would show that the treatment works as intended.)
The company is currently recruiting patients in Australia, New Zealand and the United States to participate in the trial, according to ClinicalTrials.gov.
livescience.com/64050-experimental-gluten-vaccine-nexgen2.html
Guest- Guest
Similar topics
» Scientists Have Found an ‘Off Switch’ For Celiac’s Disease
» A mix of Viagra and the flu vaccine could treat cancer: Bizarre cocktail is now being tested in humans after reducing the disease by 90% in mice
» New Health and Work Service to get long-term sick back to work
» world-first deployment of experimental electromagnetic rail ‘supergun’
» A Vaccine for Depression?
» A mix of Viagra and the flu vaccine could treat cancer: Bizarre cocktail is now being tested in humans after reducing the disease by 90% in mice
» New Health and Work Service to get long-term sick back to work
» world-first deployment of experimental electromagnetic rail ‘supergun’
» A Vaccine for Depression?
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Mar 18, 2023 12:28 pm by Ben Reilly
» TOTAL MADNESS Great British Railway Journeys among shows flagged by counter terror scheme ‘for encouraging far-right sympathies
Wed Feb 22, 2023 5:14 pm by Tommy Monk
» Interesting COVID figures
Tue Feb 21, 2023 5:00 am by Tommy Monk
» HAPPY CHRISTMAS.
Sun Jan 01, 2023 7:33 pm by Tommy Monk
» The Fight Over Climate Change is Over (The Greenies Won!)
Thu Dec 15, 2022 3:59 pm by Tommy Monk
» Trump supporter murders wife, kills family dog, shoots daughter
Mon Dec 12, 2022 1:21 am by 'Wolfie
» Quill
Thu Oct 20, 2022 10:28 pm by Tommy Monk
» Algerian Woman under investigation for torture and murder of French girl, 12, whose body was found in plastic case in Paris
Thu Oct 20, 2022 10:04 pm by Tommy Monk
» Wind turbines cool down the Earth (edited with better video link)
Sun Oct 16, 2022 9:19 am by Ben Reilly
» Saying goodbye to our Queen.
Sun Sep 25, 2022 9:02 pm by Maddog
» PHEW.
Sat Sep 17, 2022 6:33 pm by Syl
» And here's some more enrichment...
Thu Sep 15, 2022 3:46 pm by Ben Reilly
» John F Kennedy Assassination
Thu Sep 15, 2022 3:40 pm by Ben Reilly
» Where is everyone lately...?
Thu Sep 15, 2022 3:33 pm by Ben Reilly
» London violence over the weekend...
Mon Sep 05, 2022 2:19 pm by Tommy Monk
» Why should anyone believe anything that Mo Farah says...!?
Wed Jul 13, 2022 1:44 am by Tommy Monk
» Liverpool Labour defends mayor role poll after turnout was only 3% and they say they will push ahead with the option that was least preferred!!!
Mon Jul 11, 2022 1:11 pm by Tommy Monk
» Labour leader Keir Stammer can't answer the simple question of whether a woman has a penis or not...
Mon Jul 11, 2022 3:58 am by Tommy Monk
» More evidence of remoaners still trying to overturn Brexit... and this is a conservative MP who should be drummed out of the party and out of parliament!
Sun Jul 10, 2022 10:50 pm by Tommy Monk
» R Kelly 30 years, Ghislaine Maxwell 20 years... but here in UK...
Fri Jul 08, 2022 5:31 pm by Original Quill